Compare Biogen Inc (BIIB) vs Infosys Limited (INFY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Biogen Inc vs Infosys Limited — how do they compare? Biogen Inc trades at $204.1 (market cap $30.13B), while Infosys Limited trades at $12.6 (market cap $50.55B). The key difference: Infosys Limited is the larger of the two by market cap, and Infosys Limited pays a 4.16% dividend while Biogen Inc pays none. Which is the better fit depends on your goals.
| BIIB | INFY | |
|---|---|---|
Market Cap | $30.13B | $50.55B |
Sector | Health | Technology |
52-Week High | $216.63 | $20.22 |
52-Week Low | $128.93 | $10.49 |
Enterprise Value | $37.20B | $48.30B |
Dividend Yield | — | 4.16% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Biogen (BIIB) trades at $208.85, up 0.83% with bullish technical signals and strong institutional support. The company has delivered three consecutive earnings beats, with Q2 2026 EPS of $3.60 exceeding estimates by 22%. Recent acquisition of RayThera and raised 2026 guidance demonstrate strategic growth initiatives. Valuation metrics show a P/E of 36.21 and P/S of 3.01, while maintaining solid profitability with 73.99% gross margins.
Biogen presents a compelling investment case with strong earnings momentum and strategic acquisitions driving growth. However, investors face risks from declining legacy MS drug sales and net income margin compression from 16.86% in 2024 to 8.32% projected for 2026. The stock offers 12% upside to consensus price target of $234.47, supported by 62.5% analyst buy ratings.
INFY trades at $12.28, down 2.23% today, with a mixed technical picture showing bullish moving averages but overbought RSI levels. Fundamentally, the company reported Q1 2027 revenue below expectations but maintained strong margins and AI growth, with a P/E of 15.56 and robust ROE of 32.12%. Recent news includes strategic AI collaborations and a CEO transition, while analyst sentiment remains cautious with a consensus price target of $11.05.
The outlook for INFY is balanced; solid profitability and AI adoption offer upside, but near-term revenue softness and elevated valuation pose risks. Investors should weigh strong cash flow and market position against competitive pressures and execution challenges in a volatile IT services market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Biogen Inc
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021.
Read more on BIIB →About Infosys Limited
Infosys is a global leader in next-generation digital services and consulting. It enables clients in more than 50 countries to navigate their digital transformation through AI-powered cloud and data solutions.
Read more on INFY →
